| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | E Jennifer Edelman | Q86191217 |
| David A. Fiellin | Q38800653 | ||
| P2860 | cites work | Estimated HIV incidence in the United States, 2006-2009 | Q21135528 |
| Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with Men | Q24612082 | ||
| Epidemiology of HIV among injecting and non-injecting drug users: current trends and implications for interventions | Q24634237 | ||
| Antiretroviral prophylaxis for HIV prevention in heterosexual men and women | Q28270788 | ||
| HIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost-effectiveness | Q28474086 | ||
| Enrollment characteristics and risk behaviors of injection drug users participating in the Bangkok Tenofovir Study, Thailand | Q28477258 | ||
| Modeling the impact of HIV chemoprophylaxis strategies among men who have sex with men in the United States: HIV infections prevented and cost-effectiveness | Q40054244 | ||
| The first three years of buprenorphine in the United States: experience to date and future directions | Q40208514 | ||
| Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. | Q42607743 | ||
| Long-term treatment with buprenorphine/naloxone in primary care: results at 2-5 years | Q44026322 | ||
| Integration of buprenorphine/naloxone treatment into HIV clinical care: lessons from the BHIVES collaborative | Q44141522 | ||
| 1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: a randomised, placebo-controlled trial | Q44328541 | ||
| Counseling plus buprenorphine-naloxone maintenance therapy for opioid dependence | Q44331467 | ||
| Experiences of a national sample of qualified addiction specialists who have and have not prescribed buprenorphine for opioid dependence | Q44332685 | ||
| Buprenorphine versus methadone maintenance for opioid dependence | Q44340783 | ||
| A controlled trial comparing buprenorphine and methadone maintenance in opioid dependence | Q44341599 | ||
| A placebo controlled clinical trial of buprenorphine as a treatment for opioid dependence. | Q44342350 | ||
| Hepatic safety and lack of antiretroviral interactions with buprenorphine/naloxone in HIV-infected opioid-dependent patients | Q44349455 | ||
| Barriers and facilitators to primary care or human immunodeficiency virus clinics providing methadone or buprenorphine for the management of opioid dependence | Q44350023 | ||
| Nonmedical use of opioid analgesics obtained directly from physicians: prevalence and correlates | Q44351161 | ||
| Factors associated with Medicaid patients' access to buprenorphine treatment. | Q45964430 | ||
| The BHIVES collaborative: organization and evaluation of a multisite demonstration of integrated buprenorphine/naloxone and HIV treatment | Q46599155 | ||
| Blueprint for the dissemination of evidence-based practices in health care. | Q51908435 | ||
| Implementing rapid HIV testing with or without risk-reduction counseling in drug treatment centers: results of a randomized trial. | Q55169026 | ||
| A US policy perspective on oral preexposure prophylaxis for HIV | Q83866164 | ||
| Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana | Q29620078 | ||
| Training HIV physicians to prescribe buprenorphine for opioid dependence | Q30230238 | ||
| Factors affecting willingness to provide buprenorphine treatment | Q33836333 | ||
| Collaborative care of opioid-addicted patients in primary care using buprenorphine: five-year experience | Q33845768 | ||
| Mechanisms of prescription drug diversion among drug-involved club- and street-based populations | Q33887148 | ||
| HIV, transmitted drug resistance, and the paradox of preexposure prophylaxis | Q33982161 | ||
| The Physician Clinical Support System-Buprenorphine (PCSS-B): a novel project to expand/improve buprenorphine treatment | Q34050760 | ||
| A flood of opioids, a rising tide of deaths | Q34150278 | ||
| Implementation Science of Pre-exposure Prophylaxis: Preparing for Public Use | Q34448430 | ||
| Educating primary care providers about HIV disease: multidisciplinary interactive mechanisms | Q34453780 | ||
| Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings | Q34567572 | ||
| Integrating buprenorphine treatment into office-based practice: a qualitative study | Q34602077 | ||
| Packaging PrEP to Prevent HIV: An Integrated Framework to Plan for Pre-Exposure Prophylaxis Implementation in Clinical Practice | Q34680992 | ||
| Toward a comprehensive approach to HIV prevention for people who use drugs | Q34781762 | ||
| HIV/AIDS services in private substance abuse treatment programs | Q34949224 | ||
| National AIDS Hotline: HIV and AIDS information service through a toll-free telephone system | Q35055576 | ||
| Rural residence is associated with delayed care entry and increased mortality among veterans with human immunodeficiency virus infection | Q35111633 | ||
| Pre-exposure prophylaxis and antiretroviral resistance: HIV prevention at a cost? | Q35636514 | ||
| Preexposure prophylaxis for HIV prevention | Q35717688 | ||
| Health services for HIV/AIDS, HCV, and sexually transmitted infections in substance abuse treatment programs | Q35836781 | ||
| Buprenorphine: its role in preventing HIV transmission and improving the care of HIV-infected patients with opioid dependence | Q36233894 | ||
| Human immunodeficiency virus testing practices among buprenorphine-prescribing physicians | Q36249927 | ||
| The role of sexual transmission of HIV infection among injection and non-injection drug users | Q36273534 | ||
| Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: a 2-phase randomized controlled trial | Q36314619 | ||
| Barriers to obtaining waivers to prescribe buprenorphine for opioid addiction treatment among HIV physicians | Q36416746 | ||
| Why don't physicians test for HIV? A review of the US literature. | Q36881228 | ||
| Extended vs short-term buprenorphine-naloxone for treatment of opioid-addicted youth: a randomized trial | Q37030355 | ||
| Inquiries about and initiation of buprenorphine treatment in an inner-city clinic | Q37353120 | ||
| Oral preexposure anti-HIV prophylaxis for high-risk U.S. populations: current considerations in light of new findings | Q37834013 | ||
| The evidence doesn't justify steps by state Medicaid programs to restrict opioid addiction treatment with buprenorphine | Q37912872 | ||
| Attending physicians' and residents' attitudes and beliefs about prescribing buprenorphine at an urban teaching hospital. | Q39753939 | ||
| Changes in sexual risk behavior among participants in a prep hiv prevention trial | Q40022222 | ||
| Prevalence and correlates for nonmedical use of prescription opioids among urban and rural residents | Q40050494 | ||
| P433 | issue | 1 Suppl 2 | |
| P921 | main subject | pre-exposure prophylaxis against HIV | Q7239230 |
| P304 | page(s) | S86-90 | |
| P577 | publication date | 2013-01-01 | |
| P1433 | published in | American Journal of Preventive Medicine | Q4744265 |
| P1476 | title | Moving HIV pre-exposure prophylaxis into clinical settings: lessons from buprenorphine | |
| P478 | volume | 44 |
| Q35626674 | A Brief Screening Tool to Assess the Risk of Contracting HIV Infection Among Active Injection Drug Users |
| Q34022199 | HIV providers' perceived barriers and facilitators to implementing pre-exposure prophylaxis in care settings: a qualitative study |
| Q92343676 | Preferences for implementation of HIV pre-exposure prophylaxis (PrEP): Results from a survey of primary care providers |
| Q44564249 | Update to Interim Guidance for Preexposure Prophylaxis (PrEP) for the Prevention of HIV Infection: PrEP for injecting drug users |
Search more.